CG Oncology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting a net loss of $56.9 million for the third quarter and $196.1 million for the nine months ended September 30, 2026.

Key Highlights

  • Net loss (Q3 2026): $56,891 thousand, compared to $43,808 thousand in Q3 2025, as reported in the filing.
  • Nine-month net loss: $196,149 thousand for the nine months ended September 30, 2026, versus $119,686 thousand in the same period of 2025.
  • Total revenues (nine months): $3,844 thousand for the nine months ended September 30, 2026, up from $1,718 thousand in the same prior-year period.
  • Total assets: $1,046,670 thousand as of September 30, 2026, compared to $791,592 thousand as of December 31, 2025.
  • Marketable securities: $956,211 thousand as of September 30, 2026, up from $709,665 thousand at year-end 2025.
  • Shares outstanding: 89,318,916 shares of common stock as of November 4, 2026, per the filing.
  • Follow-on public offering: Proceeds of $391,410 thousand, net of issuance costs, were raised in Q1 2026, according to the stockholders' equity statement.

CG Oncology's Financial Position and Operating Results for the Nine Months Ended September 30, 2026

According to the filing, CG Oncology, Inc. (NASDAQ:CGON) reported total revenues of $1,604 thousand for Q3 2026, compared to $1,666 thousand in Q3 2025. For the nine months ended September 30, 2026, total revenues were $3,844 thousand, up from $1,718 thousand in the comparable prior-year period. The company reported commercial and development revenue of $3,820 thousand and license and collaboration revenue of $24 thousand for the nine-month period.

Total operating costs and expenses for the nine months ended September 30, 2026 were $219,883 thousand, compared to $143,792 thousand in the same period of 2025, according to the filing. Research and development expenses were the largest component at $137,608 thousand for the nine months, while general and administrative expenses totaled $72,719 thousand. Cost of sales for the nine-month period was $9,556 thousand. The resulting loss from operations for the nine months was $216,039 thousand, the filing stated.

The company disclosed total assets of $1,046,670 thousand as of September 30, 2026, with marketable securities of $956,211 thousand representing the largest portion. Total stockholders' equity stood at $990,966 thousand, reflecting an accumulated deficit of $575,125 thousand. The company's cash used in operating activities for the nine-month period was $151,064 thousand, and net cash used in investing activities was $258,382 thousand. The filing also disclosed that the registrant is classified as a large accelerated filer and is not an emerging growth company.

What Was Disclosed

CG Oncology filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $196,149 thousand, total assets of $1,046,670 thousand, and 89,318,916 shares of common stock outstanding as of November 4, 2026.